Jones Trading Reiterates Buy Rating on Capricor Therapeutics (CAPR) as FDA review resumed

March 10, 2026 10:37 AM

Jones Trading analyst Catherine Novack reiterated a Buy rating and $51.00 price target on Capricor Therapeutics (NASDAQ: CAPR)The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found